Guidelines


Annals of Oncology

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment...

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 1%-1.8% of all cancers and is the second most common haematological malignancy with an estimated incidence in Europe of 4.5-6.0/100 000/year.

Visit website
Lancet Guidelines

Treatment of relapsed and refractory multiple myeloma: recommendations from the ...

This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma.

Visit website
Immunotherapy Web Featured Images 119

Diagnosis, grading and management of toxicities from immunotherapies in children...

In this Consensus Statement, members of several international societies collaborated to provide updated comprehensive recommendations for the care of children, adolescents and young adults receiving cancer immunotherapies.

Visit website
Immunotherapy Web Featured Images 116

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immuno...

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups.

Visit website
Immunotherapy Web Featured Images 115

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for...

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies.

Visit website
Immunotherapy Web Featured Images 103

SITC clinical practice guideline on immune effector cell-related adverse events

The SITC convened a panel to discuss the recognition and management of common toxicities in the context of IEC treatment, including baseline laboratory parameters for monitoring, timing to onset, and pharmacological interventions, ultimately forming evidence- and consensus-based recommendations to assist medical professionals in decision-making and to improve outcomes for patients.

Visit website
Immunotherapy Web Featured Images 20

STIC consensus statement on immunotherapy for the treatment of multiple myeloma

SITC convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.

Visit website
Immunotherapy Web Featured Images 104

SITC clinical practice guideline on immunotherapy for the treatment of acute leu...

his publication represents an update to the previously published consensus statement based on a more recent assessment of the peer-reviewed literature and the clinical experience of expert panel participants. These recommendations are not intended to supplant sound clinical judgment but rather to provide clinicians with the most current thinking on how experts integrate immunotherapy into the treatment of patients with acute leukemia.

Visit website
Immunotherapy Web Featured Images 82

Recommendations for screening, monitoring, prevention, and prophylaxis of infect...

Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases.

Visit website
Immunotherapy Web Featured Images 28

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommend...

The European Society for Blood and Marrow Transplantation (EBMT) has therefore developed recommendations for transplant programs and physicians caring for these patients. These guidelines were developed by experts from the Infectious Diseases Working Party and have been endorsed by EBMT's scientific council and board.

Visit website